Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Minimal residual disease (MRD) is associated with adverse outcome in AML after myeloablative (MA) hematopoietic cell transplantation (HCT). We compared this association with that seen after nonmyeloablative (NMA) conditioning in 241 adults receiving NMA (n=86) or MA (n=155) HCT for AML in first remi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Walter, Roland B., Gyurkocza, Boglarka, Storer, Barry E., Godwin, Colin D., Pagel, John M., Buckley, Sarah A., Sorror, Mohamed L., Wood, Brent L., Storb, Rainer, Appelbaum, Frederick R., Sandmaier, Brenda M.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4254901/
https://ncbi.nlm.nih.gov/pubmed/24888275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2014.173
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars